Results 191 to 200 of about 7,897,516 (385)

The Possibility of Increasing Milk and Butterfat Production by the Administration of Drugs. II

, 1921
Andrew C. McCandlish, T. M. Olson
openalex   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Addressing Model Overcomplexity in Drug-Drug Interaction Prediction With Molecular Fingerprints [PDF]

arXiv
Accurately predicting drug-drug interactions (DDIs) is crucial for pharmaceutical research and clinical safety. Recent deep learning models often suffer from high computational costs and limited generalization across datasets. In this study, we investigate a simpler yet effective approach using molecular representations such as Morgan fingerprints ...
arxiv  

Practical Method of Drug Administration in a Peripheral Hospital [PDF]

, 1968
W. J. H. Leckie, H. Clansey
openalex   +1 more source

Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?

Pharmaceutical Research, 2019
Abdullah Al Shoyaib, S. Archie, V. Karamyan   +2 more
semanticscholar   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

U.S. Food and Drug Administration

, 1951

openalex   +2 more sources

United States Food and Drug Administration and the Pharmaceutical Industry [PDF]

, 1961
Jane Garland
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development

Clinical and Translational Science, 2023
Sriram Subramaniam, Stacy S. Shord, Ruby Leong, Kelly Norsworthy, Atiqur Rahman, Brian Booth, Olanrewaju Okusanya   +6 more
doaj   +1 more source